La trashumancia en Asturias: una aproximación transdisciplinar a su estudio y gestión patrimonial

[ES] Este trabajo examina las características de la trashumancia como elemento patrimonial de carácter inmaterial. Las prácticas trashumantes reconocibles en Asturias sirven de base para la reflexión, con el objetivo de informar debates de mayor alcance relacionados con la investigación y la gestión del Patrimonio Cultural Inmaterial. Al considerar las bases que definen la trashumancia, se señala la dificultad de reducir su caracterización a determinados aspectos materiales o inmateriales, ensalzando su transversalidad, que necesariamente debe superar la dicotomía material/inmaterial para enriquecer los debates en torno a su conocimiento científico y reforzar los modelos de gobernanza que afectan a su salvaguarda. Las prácticas trashumantes suponen un objeto de atención que desborda los límites tradicionales de las disciplinas científicas. Su investigación debe ser abordada desde bases teórico-metodológicas transdisciplinares. Sólo así se identificarán puntos de encuentro que catalicen estudios más complejos de esta manifestación. Del mismo modo, la adopción de una mirada transdisciplinar reforzará la colaboración entre diferentes departamentos e instituciones relevantes para su gestión.González-Álvarez, D.; Fernández-Piñar, C.; Solana-Muñoz, A. (2023). La trashumancia en Asturias: una aproximación transdisciplinar a su estudio y gestión patrimonial. Editorial Universitat Politècnica de València. 547-554. https://doi.org/10.4995/Icomos2022.2022.1534254755

Switching from subcutaneous to oral semaglutidein type 2 diabetes: A prospective study

Funding for open access charge: Universidad de Málaga / CBU

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

BACKGROUND AND OBJECTIVES: To study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN). METHODS: Patients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up. RESULTS: Forty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients. DISCUSSION: Anti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Seedless watermelons: from the microscope to the table through the greenhouse

Proceedings of the I Congress PIIISA celebrado en la Estación Experimental del Zaidín (Granada), en mayo de 2013.Seedless triploid varieties of watermelon (Citrullus lanatus var. lanatus) are very appreciated by consumers, but its production is limited because pollen donor diploid plants and insectassisted pollination is required. To improve this process it is necessary to better study pollen biology aspects such as pollen viability and germinability during long-term storage, stigma receptivity period, etc. In this work we have compared the morphology and ultrastructure of triploid and diploid plant-derived pollen grains in commercial varieties using diverse microscopy techniques. We have not detected at this stage key macroscopic morphological differences between diploid and triploid flowers. Anther development within the triploid flower is highly asynchronous. Microspores from triploid plants are larger than those from diploid plants and showed symptoms of cytoplasmic degeneration. Pollen grains from triploid plants present different morphologies, contain three isodiametric pores but colpi are sometimes not well developed. Moreover, and also depending on the hydration stage, the pollen surface is sometimes smooth, without the characteristic reticulate pattern present in pollen grains from diploid plants. All these developmental features may lead to infertility of triploid plant-derived pollen.This work was supported by ERDF-co-financed projects BFU2011-22779 (Spanish Ministry of Science and Innovation), P2010-AGR-6274, P2010-CV-I5767, and P2011-CVI-7487 (Junta de Andalucía), and RECUPERA2020 3.1.4 (Spanish Ministry of Economy and Competitiveness/ CSIC).Peer reviewe

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

BACKGROUND AND OBJECTIVES: To study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN). METHODS: Patients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up. RESULTS: Forty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients. DISCUSSION: Anti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab